Zura Bio
ZURA on Nasdaq. Zura Bio develops medicines for patients with autoimmune and inflammatory diseases. Market value $377m.
Price checks use the past 12 months to June 2026. Some use the latest annual report instead, as marked. Quality checks use five annual reports, the latest for the year to December 2025.
We can't read total debt from the filing, so debt is left out.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
Nothing stands out yet.
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $-17.11 of spare cash last year. A savings account pays about $4.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: not known. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.
$3.96 a share, 26% above its 1-year low
Over the past year the price has ranged from $3.15 to $7.44.
Pays no dividend
Prices from Tuesday’s close (6 October).
Five years of cash, in billions
| Revenue | ||||
| Revenue | n/a | n/a | n/a | n/a |
| Operating margin | ||||
| Operating margin | n/a | n/a | n/a | n/a |
| Debt to equity | ||||
| Debt to equity | n/a | n/a | n/a | n/a |
| Shares outstanding | ||||
| Shares outstanding | 0.04bn | 0.07bn | 0.07bn | 0.10bn |
Health checks
- Free cash flow positive0 of 2 years
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)Not enough data
- Profit backed by cash (accruals)Yes
- DebtUnknown
- Revenue growth, five yearsUnknown
- Buying back its own sharesNo, 120% more shares since 2022
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- A loss of $26 million, compared with a loss of $16 million a year ago.
- 34% more shares than a year ago. Each share owns a bit less of the company.
| Quarter to | Amount |
|---|---|
| September 2024 | -$21m |
| December 2024 | -$14m |
| March 2025 | -$17m |
| June 2025 | -$16m |
| September 2025 | -$18m |
| December 2025 | -$17m |
| March 2026 | -$24m |
| June 2026 | -$26m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 19 March 2026
- Next quarterly (estimated, 10-Q)
- 10 November 2026
Who owns it
None of the long-term investors we follow own it. 95 funds in all.
Largest holders overall
- Montanova Capital$56mAdded
- Venrock Adviser$38m
- MPM Bioimpact$26mNew
- Great Point Partners$25m
- JPMorgan Chase$25mCut
- Braidwell LP$23m
- Siren, L.L.C.$22m
- BlackRock$21mAdded
- Commodore Capital LP$19m
- Adage Capital Partners GP, L.L.C.$16m
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
8 investors own more than 5%.
- AI Biotechnology LLCPassive investorat least 18.2%−1.7 pts(filed with 3 related holders)Since 26 February 2026
- Athanor CapitalPassive investorat least 15.7%0.0 pts(filed with 1 related holder)Since 23 January 2026
What they said
The securities reported herein were acquired by the Reporting Persons for investment purposes in the ordinary course of business. The Reporting Persons acquired the securities without the purpose or effect of changing or influencing the control of the Issuer and do not have any…
Read the filing - UGS Capital LLCPassive investor15.7%Since 29 December 2025
- Venrock Healthcare Capital Partners III, L.P.Passive investorat least 9.9%0.0 pts(filed with 6 related holders)Since 31 March 2026
- Suvretta Capital Management, LLCPassive investorat least 9.9%+1.3 pts(filed with 2 related holders)Since 31 March 2026
- RA Capital Management, L.P.Passive investorat least 4.9%(filed with 3 related holders)Since 31 December 2024
- Great Point Partners, LLCPassive investorat least 4.4%−0.7 pts(filed with 2 related holders)Since 31 March 2026
- ADAR1 Capital Management, LLCPassive investorat least 3.2%(filed with 2 related holders)Since 31 December 2024
- JPMORGAN CHASE & COPassive investorSold down below 5%Since 30 April 2026
- Pfizer Inc. 13-5315170Passive investorSold down below 5%Since 31 December 2024
- Deep Track Capital, LPPassive investorSold down below 5%Since 30 September 2025
| Holder | Stake | Since | |
|---|---|---|---|
AI Biotechnology LLC Passive investor | at least 18.2%−1.7 pts (filed with 3 related holders) | 26 February 2026 | |
Athanor Capital Passive investor | at least 15.7%0.0 pts (filed with 1 related holder) | 23 January 2026 | What they saidThe securities reported herein were acquired by the Reporting Persons for investment purposes in the ordinary course of business. The Reporting Persons acquired the securities without the purpose or effect of changing or influencing the control of the Issuer and do not have any… Read the filing |
UGS Capital LLC Passive investor | 15.7% | 29 December 2025 | |
Venrock Healthcare Capital Partners III, L.P. Passive investor | at least 9.9%0.0 pts (filed with 6 related holders) | 31 March 2026 | |
Suvretta Capital Management, LLC Passive investor | at least 9.9%+1.3 pts (filed with 2 related holders) | 31 March 2026 | |
RA Capital Management, L.P. Passive investor | at least 4.9% (filed with 3 related holders) | 31 December 2024 | |
Great Point Partners, LLC Passive investor | at least 4.4%−0.7 pts (filed with 2 related holders) | 31 March 2026 | |
ADAR1 Capital Management, LLC Passive investor | at least 3.2% (filed with 2 related holders) | 31 December 2024 | |
JPMORGAN CHASE & CO Passive investor | Sold down below 5% | 30 April 2026 | |
Pfizer Inc. 13-5315170 Passive investor | Sold down below 5% | 31 December 2024 | |
Deep Track Capital, LP Passive investor | Sold down below 5% | 30 September 2025 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought or sold on the open market in the last 12 months.
From Form 4 filings: insiders must report trades in their own company's shares within two days.
What could go wrong
Cheap for a reason is the question the numbers cannot answer.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.